

Australian Government

Department of Health

Therapeutic Goods Administration

Public Summary

,		
Summary for ARTG Entry:	292182	Zinc Citrate
ARTG entry for	Medicine Listed	
Sponsor	Bio-Practica Pty	Ltd
Postal Address	651 Portrush Roa Australia	ad, GLEN OSMOND, SA, 5064
ARTG Start Date	28/07/2017	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	3
Conditions		

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1. Zinc Citrate	9					
Product Type	Single Medicine Product	Effective Date	28/07/2022			
Permitted Indicati	ons					
Antioxidant/Reduce	e free radicals formed in the body					
Maintain/support he	ealthy eye function					
Maintain/support eye health						
Maintain/support healthy eyesight/vision						
Maintain/support he	Maintain/support healthy growth and development					
Maintain/support ge	Maintain/support general health and wellbeing					
Maintain/support hair health						
Maintain/support nail health/strength/thickness						
Maintain/support connective tissue health						
Maintain/support be	one health					
Maintain/support di	igestion/assimilation of nutrients					
Maintain/support in	nmune system health					
Maintain/support he	ealthy immune system function					
Aid/assist/helps glu	icose/sugar/carbohydrate metabolism					
Aid/assist/helps pro	otein synthesis in the body					
Helps prevent dietary (state vitamin/mineral/nutrient) deficiency						
Maintain/support nervous system health						
Maintain/support ne	us system health					
Maintain/support ne	ervous system function					
Maintain/support healthy reproductive hormones						
Helps maintain/sup	port testosterone formation/synthesis					
Maintain/support sp	perm production					
Maintain/support sl	kin health					
Maintain/support sl	kin integrity/structure					
Maintain/support sl	kin regeneration					
Maintain/support w	ound healing					
Maintain/support sl	kin repair/healing/regeneration					
Page 1 of 2			Produced at 04.08.2022 at 03:08:20	AEST		

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown. Visit www.tga.gov.au for contact information



Australian Government

Department of Health

Therapeutic Goods Administration

Indication Requirements

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Product presentation must not imply or refer to serious immunological diseases.

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Label statement: If symptoms persist, talk to your health professional.

Product presentation must not imply or refer to vision correction, faults or serious eye disease e.g. macular degeneration.

Product presentation must not imply or refer to infertility.

Product presentation must not imply or refer to lowering or raising blood sugar/glucose levels from outside of the normal healthy range.

Product presentation must not imply or refer to hormone imbalances.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

WARNING: May be dangerous if taken in large amounts or for a long period. OR WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).

Additional Product information

Pack Size/Poison information	on		
Pack Size		Poison Schedule	
Components			
1. Formulation 1			
Dosage Form	Capsule, hard		
Route of Administration	Oral		
Visual Identification			
Active Ingredients			
zinc citrate dihydrate			155.8 mg
Equivalent: zinc			50 mg
Other Ingredients (Excipie	ents)		
Gelatin			
magnesium stearate			
microcrystalline cellulose			
purified water			

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

Page 2 of 2

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown. Visit www.tga.gov.au for contact information